We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » EXPERT: STATE LAWS BANNING RX DATA SALES COULD SPUR FEDERAL LAW

EXPERT: STATE LAWS BANNING RX DATA SALES COULD SPUR FEDERAL LAW

May 16, 2006

The U.S. government may step in to regulate the use of doctors' prescription data if states create a "bureaucratic headache" by imposing their own laws, according to one expert.

New Hampshire Gov. John Lynch plans to sign a bill that would make his state the first to effectively ban pharmaceutical companies from acquiring such data, according to a spokeswoman for the governor's office. The state House of Representatives passed the bill late May 11, following the lead of the state Senate, which approved the measure on May 4.

"There might be a push to come up with a national standard that states have to comply with," a representative of a Washington, D.C. think tank, who asked not to be identified, told FDAnews. "One of the complaints from companies is that when states impose their own policies that conflict with policies in other states, it creates a huge bureaucratic nightmare."

This is similar to the situation pharmaceutical manufacturers face with a mandate from seven states and the District of Columbia to make sure their IT systems can provide a record of the gifts their sales representatives have made to physicians. Since laws vary from state to state, pharma sales IT systems face the complicated task of tracking all these variations in reporting requirements, sometimes even for the same individual doctors if they maintain offices in two different states.

The New Hampshire law would prevent pharmaceutical benefit managers, insurance companies, data-mining companies and all types of pharmacies from selling, transferring, using or licensing prescription information for any commercial purpose. This includes any purpose that "could be used to influence sales or market share of a pharmaceutical product [or] influence or evaluate the prescribing behavior of an individual health care professional."

Currently, drugmakers buy information about what drugs doctors prescribe, and use the data to craft sales strategies for their drug products. Some lawmakers are concerned drug sales representatives may be using the information to try to change a doctor's prescribing habits, such as pressuring them to write more prescriptions for a drug or fewer prescriptions for a competing drug. (http://www.fdanews.com/did/5_96/)

KEYWORDS FDAnews Drug Daily Bulletin

Upcoming Events

  • 08Sep

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 20Sep

    Building a World-Class Pharmaceutical Advertising and Promotion Review Program

  • 21Sep

    The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

  • 22Sep

    FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

  • 11Oct

    1st Annual Quality Management vSummit

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • AngioDynamics Gets Expanded Clearance for Auryon Atherectomy System

  • Aura Biosciences Receives Fast Track Designation for Bladder Cancer Candidate

  • FDA Issues Update on Becton Dickinson’s Recall

  • FDA Grants Accelerated Approval to Enhertu for HER2-Mutant NSCLC

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing